title: In vitro chemoresponse in metachronous pairs of ovarian cancers.
abstract: OBJECTIVE
  An in vitro chemoresponse assay may aid effective therapy selection in epithelial ovarian cancer (EOC). This study explores changes in chemoresponse between paired primary and recurrent EOC tumors.
  
  
  METHODS
  RESULTS from metachronous tumors were examined in 242 patients. Changes in in vitro chemoresponse, measured by the area under the dose response curve (AUC) between paired tumors were assessed.
  
  
  RESULTS
  A significant increase in AUC was identified in most first-line therapies over time. No significant difference was observed in most recurrent therapies. When the elapsed time between occurrences was <17 months, no difference was observed for any recurrent therapies, and half of first-line therapies exhibited significant increases in AUC. When ≥17 months, all 7 therapies showed significant increases.
  
  
  CONCLUSIONS
  These results suggest an increase in chemoresistance over time, which is more pronounced for first-line therapies. This is consistent with clinical observations and suggests the biologic concordance between assay results and response to chemotherapy.
authors.affiliation: The University of Texas M. D. Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, Houston, TX, U.S.A.
authors.forename: Heather J
authors.initials: HJ
authors.lastname: Dalton
authors.affiliation: First Physicians Group Gynecologic Oncology, Sarasota, FL, U.S.A.
authors.forename: James V
authors.initials: JV
authors.lastname: Fiorica
authors.affiliation: University of Pittsburgh, Department of Obstetrics, Gynecology & Reproductive Sciences, Pittsburgh, PA, USA.
authors.forename: Robert P
authors.initials: RP
authors.lastname: Edwards
authors.affiliation: Arizona Center for Cancer Care, Gynecologic Oncology, Phoenix, AZ, U.S.A.
authors.forename: Ivor
authors.initials: I
authors.lastname: Benjamin
authors.affiliation: University of South Alabama Mitchell Cancer Institute, Gynecologic Oncology, Mobile, AL, U.S.A.
authors.forename: Rodney P
authors.initials: RP
authors.lastname: Rocconi
authors.affiliation: Florida Atlantic University, Obstetrics and Gynecology, Boca Raton, FL, U.S.A.
authors.forename: Fernando O
authors.initials: FO
authors.lastname: Recio
authors.affiliation: North Shore-LIJ Medical Group, Division of Gynecologic Oncology, Manhasset, NY, U.S.A.
authors.forename: John L
authors.initials: JL
authors.lastname: Lovecchio
authors.affiliation: Georgia Gynecology Oncology, Atlanta, GA, U.S.A.
authors.forename: Matthew O
authors.initials: MO
authors.lastname: Burrell
authors.affiliation: Abington Memorial Hospital, Hanjani Institute for Gynecologic Oncology, Department of OB/GYN, Reproductive Sciences, Abington, PA, U.S.A.
authors.forename: Mark S
authors.initials: MS
authors.lastname: Shahin
authors.affiliation: Fort Myers Obstetricians & Gynecologists, Fort Myers, FL, U.S.A.
authors.forename: Edward C
authors.initials: EC
authors.lastname: Grendys
authors.affiliation: Precision Therapeutics, Department of Biology R & D, Pittsburgh, PA, U.S.A. dwang@ptilabs.com.
authors.forename: Dakun
authors.initials: D
authors.lastname: Wang
authors.affiliation: Precision Therapeutics, Department of Biology R & D, Pittsburgh, PA, U.S.A.
authors.forename: Tianhua
authors.initials: T
authors.lastname: Wang
authors.affiliation: University of Arizona Cancer Center-Phoenix Creighton University School of Medicine at St. Joseph's, Department of Obstetrics and Gynecology, Phoenix, AZ, U.S.A.
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Monk
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000401:mortality; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000401:mortality; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000970:Antineoplastic Agents
keywords: Chemoresponse; chemotherapy; primary ovarian cancer; recurrent ovarian cancer